Literature DB >> 8391178

Factors affecting retroviral vector function and structural integrity.

J R McLachlin1, N Mittereder, M B Daucher, M Kadan, M A Eglitis.   

Abstract

Recombinant retroviruses are widely used for gene transfer into eukaryotic cells and exhibit significant potential for human gene therapy. Despite the utility of retroviral vectors, their design is still essentially empirical. We have constructed a series of reciprocal, double-gene vectors to compare the dual expression of beta-galactosidase (beta-gal) and neomycin phosphotransferase (neor) in a retroviral delivery system. The first gene of the pair was driven by the viral LTR promoter and the internal gene was regulated by either the SV40 virus early promoter or the cytomegalovirus (CMV) major late promoter. Clones of vector producer cells were isolated either by G418 selection for expression of neor, or by fluorescence-activated cell sorting for expression of beta-gal, and the activity of both genes was evaluated. In general, vectors using the SV40 promoter performed better than those with the CMV promoter, regardless of whether the selected gene was regulated by the LTR or the internal promoter. Southern analysis of clones indicated that loss of beta-gal gene function was related to significant rearrangements and deletions in vector structure. We also found that the arrangement of genes within the vector was important. When beta-gal preceded neor, gene expression and vector stability were markedly enhanced relative to vectors containing these genes in the inverse order.

Entities:  

Mesh:

Year:  1993        PMID: 8391178     DOI: 10.1006/viro.1993.1340

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  Generation of stable recombinant retroviruses containing the beta-globin genes linked to complex regulatory elements by using transient transfection.

Authors:  B Li; D Liu; J Wang; W Dong; C C Liang
Journal:  Mol Biotechnol       Date:  1999-11       Impact factor: 2.695

2.  Extended analysis of the in vitro tropism of porcine endogenous retrovirus.

Authors:  C A Wilson; S Wong; M VanBrocklin; M J Federspiel
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 3.  Hepatocyte Transplantation: Quo Vadis?

Authors:  Mark Barahman; Patrik Asp; Namita Roy-Chowdhury; Milan Kinkhabwala; Jayanta Roy-Chowdhury; Rafi Kabarriti; Chandan Guha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-29       Impact factor: 7.038

4.  Fungal phosphate transporter serves as a receptor backbone for gibbon ape leukemia virus.

Authors:  L Pedersen; M van Zeijl; S V Johann; B O'Hara
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Mutational analysis of the proposed gibbon ape leukemia virus binding site in Pit1 suggests that other regions are important for infection.

Authors:  G J Chaudry; M V Eiden
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Single amino acid insertion in loop 4 confers amphotropic murine leukemia virus receptor function upon murine Pit1.

Authors:  M D Lundorf; F S Pedersen; B O'Hara; L Pedersen
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

7.  Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line.

Authors:  P Malik; S A McQuiston; X J Yu; K A Pepper; W J Krall; G M Podsakoff; G J Kurtzman; D B Kohn
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 8.  Development of retroviral vectors as safe, targeted gene delivery systems.

Authors:  W H Günzburg; B Salmons
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

9.  Properties of a unique form of the murine amphotropic leukemia virus receptor expressed on hamster cells.

Authors:  C A Wilson; K B Farrell; M V Eiden
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.

Authors:  M Grompe; K Overturf; M al-Dhalimy; M Finegold
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.